Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

NOHARM MTD is an extension of a previous study for children with Sickle Cell Anemia (SCA) who were enrolled in the NOHARM study. All children enrolled in NOHARM received hydroxyurea treatment at a fixed daily dose of 20 mg/kg/day. This dose was selected as a likely safe dose, but does not escalate hydroxyurea to maximum tolerated dose "MTD" as is commonly done in the US. Without this information, we cannot know whether hydroxyurea treatment at the MTD would be feasible (since it requires closer monitoring to avoid hematological toxicities), safe (since adverse events may be greater with MTD, risk of malaria may be altered by MTD, and risk of infections as a result of neutropenia could also be greater with MTD) or beneficial (MTD is associated with higher hemoglobin and fetal hemoglobin concentration).

NCT Number	NCT07708714
Lead Sponsor	Children's Hospital Medical Center, Cincinnati Collaborators: Makerere University, Indiana University, Indian Institute of Science, Mulago Hospital, Uganda
Conditions	Sickle Cell Disease, Sickle Cell Anemia in Children
Enrollment	250 participants
Start Date	2026-05-13
Primary Completion	2030-11-30 (estimated)
Study Completion	2032-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-16